Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study

نویسندگان

چکیده

BackgroundMiddle-income countries (MICs) that are not eligible for funding from Gavi, the Vaccine Alliance, have been slow to adopt rotavirus vaccines. Few studies evaluated cost-effectiveness and benefit–risk of vaccination in these settings. We aimed assess potential economic health impact 63 MICs Gavi.MethodsIn this modelling study, we estimated Gavi funding. used an Excel-based proportionate outcomes model with a finely disaggregated age structure estimate number gastroenteritis cases, clinic visits, hospitalisations, deaths averted by children younger than 5 years over 10-year period. calculated ratios (costs per disability-adjusted life-years compared no vaccination) (number hospitalisations due excess intussusception). three alternative vaccines available globally (Rotarix, Rotavac, Rotasiil) information vaccine manufacturers regarding anticipated prices. ran deterministic probabilistic uncertainty analyses.FindingsOver period 2020–29, could avert 77 million (95% interval [UI] 51–103) cases 21 (12–36) 3 (1·4–5·6) 37 900 (25 900–55 900) support. From government perspective, would be cost-effective 48 (77%) 62 considered. The ratio prevented versus those potentially caused exceeded 250:1 all countries.InterpretationIn most funding, has high probability favourable profile. Policy makers should consider new evidence when making or revisiting decisions on use their respective countries.FundingBill & Melinda Gates Foundation. Middle-income Gavi. In analyses. Over countries.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.

Rotavirus is the leading cause of diarrheal disease in children under 5 years of age. It is responsible for more than 450,000 deaths each year, with more than 90% of these deaths occurring in low-resource countries eligible for support by the GAVI Alliance. Significant efforts made by the Alliance and its partners are providing countries with the opportunity to introduce rotavirus vaccines into...

متن کامل

Health and economic impact of rotavirus vaccination in GAVI-eligible countries

BACKGROUND Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the e...

متن کامل

Comparative evaluation of the potential impact of rotavirus versus hpv vaccination in GAVI-eligible countries: A preliminary analysis focused on the relative disease burden

BACKGROUND Immunization policymakers at global and local levels need to establish priorities among new vaccines competing for limited resources. However, comparison of the potential impact of single vaccination programs is challenging, primarily due to the limited number of vaccine analyses as well as their differing analytic approaches and reporting formats. The purpose of this study is to pro...

متن کامل

Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries

BACKGROUND Most health economic evaluations of childhood vaccination only capture the health and short-term economic benefits. Measuring broader, long-term effects of vaccination on productivity and externalities could provide a more complete picture of the value of vaccines. METHOD MEDLINE, EconLit and NHS-EED databases were searched for articles published between January 1990 and July 2011,...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: The Lancet Global Health

سال: 2021

ISSN: ['2214-109X', '2572-116X']

DOI: https://doi.org/10.1016/s2214-109x(21)00167-4